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【要約】 
 
 
Persistent hyperleptinemia enhances tau pathology with increased 
astrocytic leptin receptor expression in obese tauopathy model mice 
（肥満タウオパチーモデルマウスにおいて， 
持続的な高レプチン血症がアストロサイトの 
レプチン受容体の発現亢進を伴うタウ病理を増強する） 
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ABSTRACT 
The number of patients with Alzheimer’s disease (AD) is increasing worldwide, and 
available drugs have shown limited efficacy. Hence, preventive interventions and 
treatments for presymptomatic AD are currently considered very important. Obesity 
rates have also been increasing dramatically and it is an independent risk factor of AD 
Therefore, for the prevention of AD, it is important to elucidate the pathomechanism 
between obesity and AD. We generated high calorie diet (HCD)-induced obese 
tauopathy model mice (PS19), which showed hyperleptinemia but not insulin resistance. 
HCD enhanced tau pathology and glial activation. Conversely, voluntary exercise with a 
running wheel normalized the serum leptin concentration without reducing body weight, 
and restored the pathological changes induced by HCD. Thus, we speculated that 
persistent hyperleptinemia played an important role in accelerating pathological changes 
in PS19 mice. Leptin primarily regulates food intake and body weight via leptin 
receptor b (LepRb). Interestingly, the nuclear staining for pAMPK, which was activated 
by LepRb, was decreased in hippocampal neurons in HCD PS19 mice, indicating leptin 
resistance. Meanwhile, astroglial activation and the astrocytic expression of a short 
LepR isoform, LepRa, were enhanced in HCD PS19 mice. Real-time PCR analysis 
demonstrated that leptin increased mRNA levels for pro-inflammatory cytokines 
including IL-1β and TNF-α in primary cultured astrocytes from wild type and 
LepRb-deficient mice. These observations suggest that persistent hyperleptinemia 
caused by obesity induces astrocytic activation, astrocytic leptin hypersensitivity with 
enhanced LepRa expression, and enhanced inflammation, consequently accelerating tau 
pathology in PS19 mice.  
 
